Private equity major ChrysCapital is set to channel a significant portion of its recently raised $2.2 billion fund into India's burgeoning pharmaceutical and healthcare industries. The firm anticipates dedicating between 20-25% of this capital, an indicative allocation of $440-550 million, to these vital sectors.
This strategic move marks an evolution in ChrysCapital's investment approach, expanding beyond its historical focus on minority stakes to include selective control investments. Kshitij Sheth, Managing Director at ChrysCapital, highlighted the firm's long-standing commitment to these areas, stating, "ChrysCapital has historically been overweight on pharma and healthcare, and the two sectors are expected to remain an important area of focus going forward."
Expanding Investment Strategy
For years, ChrysCapital primarily pursued minority positions within domestic formulation companies. However, the firm is now diversifying its strategy to encompass control deals, seeking a balanced portfolio that includes both minority and majority investments in the pharma space.
The Novartis India Acquisition
A prime example of this shift is ChrysCapital's recent acquisition of a majority stake in Novartis India. While Novartis India's revenue base of approximately ₹450 crore was smaller than ChrysCapital's typical target of around ₹1,000 crore, the deal was driven by the company's robust brand portfolio and substantial growth potential.
Novartis India boasts several brands generating over ₹30 crore each, with most holding top-two market positions in their respective categories. ChrysCapital viewed this as an excellent foundation for future growth, both organically and through inorganic opportunities.
Following the acquisition, Novartis India is undergoing significant restructuring. Its brands, previously licensed to other pharmaceutical companies for sales and distribution, will now be managed by an in-house sales force and distribution network. This transition aims to unlock the full potential of these brands.
Furthermore, Novartis India has expanded its portfolio by acquiring Pfizer's Minipress brand, marking its entry into the cardio-diabetes segment, and has secured licensing arrangements for two ophthalmology brands from Novartis Global.
Indian Pharma Market Outlook
The Indian domestic pharmaceutical market is experiencing robust growth. Valued at approximately $60 billion in FY26, it is projected to more than double to $130 billion by 2030, according to the India Brand Equity Foundation (IBEF).
Private equity investment in Indian pharma has also seen an uptick, with annual inflows rising from around $800-900 million to $1.2-1.3 billion over the past two to three years. EY data indicates that the broader PE/VC market has invested $16.4 billion across 303 deals in Indian pharmaceuticals and medical devices since 2016, with a significant 62% of that capital deployed in the last five years.
Key Investment Areas and Risks
ChrysCapital's core interest lies in domestic formulations, particularly companies focused on chronic therapies. The firm also identifies strong growth potential in Active Pharmaceutical Ingredient (API) and Contract Development and Manufacturing Organization (CDMO) businesses, which have attracted around 60% of recent pharma investments due to Indian companies gaining global customers and enhancing chemistry capabilities.
However, ChrysCapital remains cautious about export formulations, especially those heavily reliant on the US generic market. This segment faces challenges such as price erosion, stringent US FDA inspections, and the risk of tariffs. Similarly, while API businesses initially benefited from the "China Plus One" strategy, they have recently navigated a cyclical global pricing environment, though some "green shoots" are now emerging.
Consolidation and Valuation Opportunities
The firm anticipates continued consolidation within the fragmented Indian pharma market, driven by acquisitions from major players like Sun Pharma, Torrent Pharma, Mankind Pharma, and Eris Lifesciences. Additionally, many family-owned pharma businesses, whose founders have run them for decades, are now seeking to sell, creating further deal opportunities.
With historical pharma growth rates moderating from 15-16% to 9-10%, Sheth emphasized the need for active investment strategies, focusing on inorganic growth through mergers and acquisitions, alongside margin improvement.
ChrysCapital is actively seeking businesses with strong inherent capabilities that may currently be undervalued by the market, presenting attractive entry points. The firm aims to identify companies with solid fundamentals whose valuations have not yet reached the heights of top-performing peers.